Medical Design Briefs - July 2024 - 34

Design Briefs
3000
2500
2000
1500
1000
500
2023
Source: Clarivate
Fig. 1 - Global PFA market value.
8000
7000
6000
5000
4000
3000
2000
1000
2023
SCS Devices
DBS Devices
SNS Devices
VNS Devices
2028
Tibial nerve stimulation (U.S. only )
HGNS Devices
Fig. 2 - Neurostimulation device market, U.S. and Europe 2023 and 2028.
" Despite the challenges of the past five
years, the medtech industry has shown
remarkable resilience, driving forward
with groundbreaking technological advancements, "
says April Chan-Tsui, director,
medtech insights, life sciences &
healthcare at Clarivate. " Backed by indepth
industry expertise and robust
data, this report highlights recent breakthroughs
poised to significantly improve
patient outcomes. These innovations
represent the forefront of medtech's
journey towards extraordinary impact. "
34
The five 2024 medical technologies
to watch are pulsed field ablation devices,
diabetes care devices, neurostimulation
devices, surgical robotics, and renal
denervation.
Pulsed field ablation devices. Pulsed
field ablation (PFA) has emerged as a
promising treatment for atrial fibrillation
(AF), garnering significant attention
from the cardiac ablation community.
PFA employs electric pulses, not
heat, that help in the electroporation of
the myocardium
without collateral
www.medicaldesignbriefs.com
GE S Devices
Source: Clarivate
2024
2025
2026
2027
2028
damage to normal heart tissue. Compared
to established treatment options,
PFA has remarkably low recurrence
rates, shorter treatment durations and
higher success rates.
The PFA market, projected to reach
$3 billion by 2028, is highly lucrative, especially
considering the potential global
population of 60 million individuals with
AF (see Figure 1).
Diabetes care devices. Diabetes care
technology is poised for significant
growth in the near future, driven by ongoing
advancements. Beyond these developments,
significant activity is also
under way in developing alternative
treatment options for diabetes management,
including new drug therapies and
medical procedures that could potentially
impact the growth of the diabetes care
technology market in the coming years.
A potential hurdle for long-term adoption
of diabetes care technology is the
recent rise of GLP-1 receptor agonists
(GLP-1 RAs), due to their demonstrated
efficacy in blood sugar control in individuals
with type 2 diabetes. However,
due to the high relative penetration for
insulin pumps in the type 1 diabetic population,
GLP-1s are not expected to have
a paradigmatically strong effect on the
insulin pump market in the short term.
Neurostimulation devices. The multibillion-dollar
implantable neurostimulation
device market will grow as new
and incumbent competitors expand
treatable indications and launch new
devices with design and lifespan improvements.
The hypoglossal nerve
stimulation device (HGNS) market has,
in particular, witnessed rapid growth,
and it is expected to surpass most other
neurostimulation device markets in size
in upcoming years.
The indications treated by neurostimulation
devices - for example,
chronic pain, epilepsy, and incontinence
- can have a significant impact
on a patient's lifestyle and quality of
life, and neurostimulation devices represent
an important option for those
who have not found sufficient efficacy
in other treatments.
Surgical robotics. Surgical robotic systems
are revolutionizing the field of
medicine, offering better visualization,
increased precision, and better ergonomics
for surgeons. These systems go
beyond simple robotic systems, providing
a platform for minimally invasive surMedical
Design Briefs, July 2024
Market Value in USD M
Market value USD M
https://www.medicaldesignbriefs.com
Medical Design Briefs - July 2024

Table of Contents for the Digital Edition of Medical Design Briefs - July 2024
